Peptides DB
Research-centric peptide and protocol reference hub

Lixisenatide record · updated 6h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only
All 23 studiesJump to the evidenceCompare
What is Lixisenatide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Lixisenatide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 133 registered trials. It describes the research record, not a recommendation.

Identity
NameLixisenatide
Chain length—
Molecular weight4,858 Da
FormulaC215H347N61O65S
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 90472060. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~2.5 hours
Time to peak1–3 hours
Duration~24 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 8, 2026. How this works →
Research stats
Total studies23
Human / animal / cellular12 / 6 / 1
Highest trial phasePhase 2
Years covered2023–2026
Latest study13d ago
Publication history
20232026
Research funding
7 NIH projects · $3.1M awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports263
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

23 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States.
Finding49% reduction in affected body surface area with ruxolitinib cream.
Human2026Full text read0.80
Pyrethroid resistance intensity and mechanisms in Anopheles gambiae sensu lato (Diptera: Culicidae) from Oyo State, Nigeria.
FindingMortality for permethrin ranged from 5% (Egbeda) to 65% (Akinyele) at diagnostic dose.
Animal2026Full text read0.80
A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
FindingMedian overall survival was 7.23 months.
Human2026Full text read0.80
Clinical and inflammatory determinants of successful abrocitinib dose reduction in atopic dermatitis: a real-world cohort study with implications for treatment optimization.
FindingNot reported in abstract.
Human2026Full text read0.80
A phytotherapeutic candidate for neuropathic pain: Helicteres ovata (Lam.) extract shows antinociceptive effects and favorable acute toxicity profile.
FindingNot reported in abstract.
Animal2026Full text read0.70
Steaming reduces Polygonum multiflorum hepatotoxicity by modulating gut microbiota-bile acid-FXR/NF-κB signaling in the gut-liver axis.
FindingPPM treatment reduced serum ALT by 82% compared to the PM group.
Animal2026Full text read0.70
Interpretable feature-transformer framework for cross-subject MCI detection using nonlinear dynamical and graph-theoretic EEG features.
Finding97.04% ± 0.72 performance of the feature-based Transformer.
Human2026Full text read0.80
Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a <i>post hoc</i> analysis of a phase-III trial.
FindingEASI 75 response rates at week 16 were 81.9% in early responders vs. 47.2% in nonearly responders, p<0.001.
Human2026Full text read0.80
Physiological benefits of protected AD3E on nutrient digestibility, hematology, and small intestinal morphology and carcass characteristics in fattening lambs.
FindingFinal weight of lambs receiving protected vitamin supplement was higher than control group (P < 0.05).
Animal2026Full text read0.70
Merocyanine derivatives as theranostic agents for cognitive improvement and real-time imaging of amyloid-β in APP/PS1 transgenic mice.
Findinginhibition rate: 89.5%
Animal2026Full text read0.70
Antidepressant-like effects of valproic acid in rodents go back to the 1980s: a comment to enrich the reviewed evidence by Goudarzi et al. (2026) "Valproic acid effects on stress-induced depression-like behavior in rodent models: a systematic review and meta-analysis".
FindingNot reported in abstract.
review2026Full text read0.70
Suicidal thoughts and behaviours in Cape Town: A cross-sectional study of prevalence and social, contextual, and clinical correlates.
Finding14.0% prevalence of past 30-day suicidal ideation, n=613.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Lixisenatide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Lixisenatide is discussed should be drawn from it.